We take the time to understand your full health picture, monitor potential risks, and help you achieve sustainable, long-term results
Reported Weight-Loss Efficacy in Trial Data Across pivotal Phase 3 trials, mean weight reduction has scaled with receptor coverage
Its phase 3 drug survodutide is a GLP-1 receptor dual agonist that works by activating the glucagon and GLP-1 receptors simultaneously that are meant to reduce body weight by both boosting energy burn and reducing food intake
But separately, both forms appear to result in similar amounts of weight loss
Experts have also noted unplanned pregnancies regularly occur among people using oral contraceptives who are not using GLP-1 medications
Knowing your AMH level, antral follicle count, sperm analysis results, and hormonal profile allows a specialist to match supplement choices to your actual biology